MARKET

ANEB

ANEB

Anebulo Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.10
+0.10
+1.43%
After Hours: 7.05 -0.05 -0.70% 17:00 05/07 EDT
OPEN
7.38
PREV CLOSE
7.00
HIGH
7.48
LOW
6.72
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
7.48
52 WEEK LOW
6.72
MARKET CAP
165.19M
P/E (TTM)
-946.6667
1D
5D
1M
3M
1Y
5Y
IPOs For Friday, May 7: Bowman Consulting Group, Priced At $14/Share; Anebulo Pharmaceuticals, Priced At $7/Share; Data Knights Acquisition Corp., Priced At $10/Unit; Talaris Therapeutics, Priced At $17/Share
(NASDAQ:ANEB) (NASDAQ:DKDCU)  
Benzinga · 2d ago
Anebulo Pharmaceuticals Shares Will Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $7/Share
(NASDAQ: ANEB)  
Benzinga · 2d ago
DJ Anebulo Pharmaceuticals IPO Priced at Middle of Views >ANEB
Dow Jones · 2d ago
Anebulo Pharma seeks to raise $21M in IPO
Anebulo Pharmaceuticals (ANEB) has priced its IPO of 3M shares of common stock at $7.00/share, for expected gross proceeds of ~$21M.Underwriter's over-allotment is an additional 450K shares.Trading commences on May
Seekingalpha · 2d ago
Anebulo Pharmaceuticals Prices IPO at $7 Per Share
MT Newswires · 2d ago
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANEB. Analyze the recent business situations of Anebulo Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing solutions for people suffering from cannabinoid overdose and substance addiction. The Company's lead product candidate, ANEB-001, is a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. CB1 antagonists bind to the CB-1 receptor and thereby reverse the action of cannabinoids such as tetrahydrocannabinol (THC). It has completed Phase I trials.

Webull offers kinds of Anebulo Pharmaceuticals Inc stock information, including NASDAQ:ANEB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANEB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANEB stock methods without spending real money on the virtual paper trading platform.